Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

NCT04665076 is registered in ClinicalTrials.gov with Hebei Senlang Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT04665076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04665076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
Lead sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
October 22, 2020
Completion date
October 21, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell tumors